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Summary
Background. Hepatitis C infection (HCV) can have a harmful 
effect on the health of people and can impose relevant healthcare 
costs. The World Health Organization has identified the elimina-
tion of Hepatitis C by 2030 as an important goal for all countries. 
This study aimed to identify the HCV-related policies in Iran.
Methods. A qualitative approach was used for this study. Data 
was collected through a comprehensive search of documents and 
interviews with different stakeholders related to the HCV pro-
gram. Data was analyzed and validated using content analysis 
based on the policy triangle framework.
Results. Our findings highlighted that certain social and cul-
tural issues related to stigma can impact on awareness-raising 
processes. It is also necessary to consider HCV directly in the 
context of government policies. All relevant stakeholders should 
be included. Continued talks and interactions need to be made 
between them for the active participation of all actors. 
Conclusion. The findings of this study can provide useful informa-
tion for improving, supporting and developing policy processes. 
Healthcare providers should address all aspects of the disease by 
2030 in order to achieve the goal of HCV elimination. Evidence-
based planning, support for up-to-date policies and resource 
mobilization are needed to achieve this ambitious goal.
Introduction 
Viral hepatitis is a major public health challenge world-
wide  [1]. Hepatitis C infection (HCV), a blood-borne 
viral hepatitis, can have a harmful effect on the health of 
people and can impose relevant healthcare costs [2, 3]. 
In 2017, the World Health Organization (WHO) has es-
timated that, globally, around 71 million people have 
been infected with chronic HCV infection [4] and about 
399,000 people have developed liver cirrhosis and hepa-
tocellular carcinoma [4].
The WHO has identified the elimination of this infection 
by 2030 as a major and important objective. As such, all 
countries are required to reduce new infections by 90% 
and related deaths by 60% within 2030 [5]. To achieve 
such an ambitious goal, effective policies should be used 
to prevent and treat HCV [6]. In recent years, valuable 
advances have been made regarding epidemiological ev-
idence, diagnosis and treatment of HCV by using direct 
antiviral agents (DAAs). The use of antiviral drugs has, 
indeed, increased the rate of recovery in patients by up 
to 90% [7, 8]. This has changed management perspec-
tives: many countries have put HCV infection as a health 
priority [9-11].
Health policy-making is a complex process that exam-
ines the different dimensions of decisions, plans, role of 
various stakeholders and actions needed to be taken in 
order to achieve a health-care goal [12]. Policy analysis 
as a practice in the health sector is increasing in low- and 
middle-income countries. Paying attention to the nature 
of policies, how they are created, implemented, and af-
fect health, and how agenda setting is developed is of 
crucial importance [13]. A better understanding of pro-
cesses underlying healthcare and the acknowledgement 
of their impact on health issues can lead to an effective 
design and policy-making [14]. 
Due to the specific nature of the health sector, policy 
analysis requires more attention and sensitivity be-
cause it has a direct impact on the health of the com-
munity [13]. In Iran, the prevalence of HCV infection is 
relatively low according to epidemiological studies [15], 
especially when compared to settings such as the Middle 
East and North Arica (MENA) countries, like Pakistan 
and Egypt, even though in the last years the scenario is 
changing. According to a recent meta-analysis, the prev-
alence of HCV in the general population is estimated to 
be 0.6%  [16]. In a further meta-analysis conducted in 
blood donors in 2013, HCV prevalence is estimated to 
be 0.5% [17]. In high-risk groups, the estimated preva-
lence of HCV is 32.3% and can increase up to 43.1% 
among injection drug users (IDUs) [18]. In meta-analy-
ses in prisoners, street children and thalassemia patients, 
the prevalence of HCV has been found to be, respec-
tively, 28%, 2.4% and 19% [19-21]. In Iran, the number 
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of injecting drug users is increasing and this is reflected 
by the parallel increase in HCV infection rate: this is 
considerably changing the HCV epidemiology in the 
country [15]. 
Health systems around the world have implemented 
various strategies and programs for preventing, screen-
ing and treating HCV and achieving the WHO goal [22]. 
Understanding these policies is important in any country 
or community, and healthcare policy-makers can make 
better decisions about implementing HCV elimination 
programs by knowing more about the factors involved in 
the transmission and spread of the infection [23]. Many 
people believe that due to the seriousness of HCV for 
public health, prevention and control plans by the gov-
ernment, organizations and stakeholders at the highest 
levels should be considered. 
In Iran, the Ministry of Health and Medical Education 
(MoHME) has launched various programs  –  the last 
in 2017 –  in order to eliminate new cases of infection 
in three major areas: prevention, screening and treat-
ment [24]. The educational programs are aimed at raising 
public awareness by providing appropriate information 
related to HCV prevention [25]. Currently HCV screen-
ing is carried out passively in Iran. Across the country, 
good laboratories and facilities work to diagnose the dis-
ease [26]. In 2014, it has been estimated that there are 
about 18,6500 HCV patients in Iran [27]. By providing 
DAAs to infected patients, the National Health System 
aims to reach Sustainable Development Goals (SDGs) 
goals, and to eliminate the disease by 2030 [27].
The MoHME, in line with the upfront documentation 
of long-term national development and the fulfilment 
of the country’s international obligations, understands 
the necessity and importance to prevent and control the 
disease. The MoHME has, therefore, planned to adopt 
a comprehensive and systematic approach as well as to 
implement effective strategies to eliminate the disease 
together with the establishment of a national hepatitis 
committee. 
This study aimed to examine the HCV-related processes, 
programs, strategies, and documents in Iran, with the 
aim that identifying these policies can improve the exist-
ing gaps between the present and the desired situation.
Methods 
Ethical approval and consent to participate
This study received ethical approval from the School of 
Health Management, Iran University of Medical Sci-
ences (IR.SUMS.REC.1396.9423557001).
Research team and reflexivity
Two authors (MB and HAG) conducted the first (docu-
ments collection and review) and second (interviews) 
steps of the present investigation. The research team in-
volved has experience in conducting qualitative studies. 
For a better coordination, before the study was complet-
ed, a meeting was held and the research methodology 
process was discussed. Training events were also organ-
ized in order to better get in touch with the participants. 
Prior to conducting interviews, questions were sent to 
five experts on HCV for the pilot, and their comments 
and feedbacks were used to modify the questionnaire, if 
deemed necessary.
Study design
A qualitative policy analysis approach was used for this 
study. Data were collected through a broad and compre-
hensive search of documents and interviews with differ-
ent stakeholders related to the HCV program (Figure 1).
Documents collection and review
The first step was to review policy documents related to 
HCV. To find documents, first the MoHME website was 
searched. After finding documents in the MoHME web-
site, a list of relevant stakeholders including ministries, 
national and international organizations, companies and 
non-governmental organizations (NGOs) was prepared. 
The websites of the Parliament (Majlis) and the Expedi-
ency Discernment Council (EDC) were also searched. In 
Iran, for macro policies, the leader has a very important 
role in determining policies, and, as such, the documents 
communicated by him were also examined. The WHO 
website containing reports, policies and programs was 
also mined. In addition, international scholarly data-
bases such as PubMed/MEDLINE, Scopus, ISI/Web of 
Science (WoS) and Embase, and the national databases 
including MagIran and SID were extensively searched 
for finding relevant policies-related documents.
Interviews 
This step was based on the “Consolidated criteria for 
reporting qualitative research” (COREQ) checklist[28], 
a 32-item checklist for properly conducting qualitative 
research interviews and focus groups. These items re-
gard three major domains; namely (i) research team and 
reflexivity, (ii) study design and (iii) data analysis and 
reporting.
The number of people contacted for the interviews was 
26, of which 21 answered. They were contacted by tel-
ephone and email before the interview, and they were 
given a description of the goals and reasons for doing the 
Fig. 1. Flowchart adopted in the present investigation.
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study. For optimal use of interview time, the question-
naire was sent to them prior to the interview.
The second step comprised of interviews with diverse 
groups of respondents (n = 21), including policy-makers, 
academics involved in health policy, hepatitis special-
ists, senior researchers, senior clinicians, representatives 
of pharmaceutical companies, health directors working 
in the field of primary health care (PHC), NGOs, blood 
bank managers, nurses, laboratory managers and jour-
nalists. The key informants were identified with assis-
tance from documents collection and review and the re-
search unit at the MoHME. During the interview, snow-
balling sampling was used: the interviewees were asked 
to introduce other people who had experience or vision 
in HCV to participate in the study. Face-to-face inter-
views were conducted at workplace, clinics, or where 
the participants felt comfortable. To create a friendly and 
confident relationship – during the interview – only the 
participants and researchers were present. All the inter-
views were conducted following the proper methodol-
ogy: no interview needed to be repeated. Researchers 
recorded and took written notes of each interview.
Data collection
This study was conducted between September 2017 and 
July 2018. After the search and collection of relevant 
documents, a form was prepared and the title, content 
and year of publication of HCV-related policies and 
documents were extracted. Semi-structured, face-to-face 
interviews with participants of length varying between 
45 and 60 minutes were performed and were digitally 
recorded with their permission. Open-ended questions 
were used. Interviews continued until data saturation was 
reached. After sixteen interviews no new data emerged 
and therefore the material was considered saturated. 
Analytical framework
The policy triangle framework is a useful model for ana-
lyzing topics in the health sector. This model includes 
four components related to policy issues, such as con-
text, content, actors and process. This model can provide 
a very important framework for understanding health 
sector-related issues for policy- and decision-makers. 
This model can be used retrospectively or prospective-
ly [29]. 
Questions related to prevention, screening and treatment 
were asked. More in detail, the questions were the fol-
lowing:
1. Please describe the social, cultural, political, interna-
tional and economic dimensions of HCV disease in 
Iran. 
2. What is the structure of HCV-related policy in Iran 
since its inception concerning the prevention, screen-
ing and treatment? Which goals are being pursued in 
the country regarding the control and management of 
hepatitis C?
3. How do you see the policy process in the country? 
How are policies being developed, implemented and 
evaluated?
4. How and why are these policies taken into account? 
Why are these policies considered as one of the main 
priorities for health policy in the country?
5. Which organizations, institutions or individuals have 
a great impact on the hepatitis C policy process in 
Iran?
6. Are there other points of view regarding the state of 
policies and plans for hepatitis C in the country?
Data analysis
The policy triangle model was used as a framework 
for extraction and analysis of identified policy docu-
ments  [29]. After the recorded interviews, two authors 
transcribed them verbatim. 
Data related to each phase of the HCV disease – includ-
ing: prevention, screening and treatment – and the four 
components (context, content, actors and process) of the 
study framework were extracted from the interviews. 
Any disagreements between authors were resolved by 
discussion [30]. Data were analyzed and validated using 
content analysis. To validate the data, prolonged engage-
ment and proper interaction with participants, and care-
ful data revision helped to increase the credibility of the 
data. Also, methodological triangulation and diversity of 
sampling increased the credibility of the data and led to 
confirmability. Concerning verifiability, this was guar-
anteed by two academic members, with assistance of the 
researchers, by thorough and careful review of the text 
of the interviews, the codes, and the themes of the frame-
work until agreement was reached. The transcription of 
interviews, the use of external checks and re-reading of 
all data ensured the overall reliability of the process. Af-
ter being provided with the codes, a number of partici-
pants gave confirmation feedbacks.
Results 
Overall, 21 different experts in the field and stakeholders 
related to the HCV program in Iran were interviewed. 
The mean age of participants was 39  ±  11.3 years. 
Among them, 17 were male and 4 females.
Context 
In Iran, the general public has a negative attitude towards 
HCV. They think the disease is fatal and affects people 
who do not observe ethical issues. People believe that 
patients should be quarantined to prevent the transmis-
sion and spread of disease. Many people do not know 
enough about the ways and strategies to prevent it, and 
they consider it a terrible disease, like HIV.
“When colleagues or people understand that I suffer 
from HCV, their behaviours change. They think that I 
have committed an immoral act and stay away from me. 
People do not feel good about me and they are not even 
willing to interact with me”.
To increase awareness among people, educational activi-
ties are carried out at various levels of the health sector. 
Most of these activities take place especially in PHC, 
informing and raising awareness about HCV, but are 
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generally poor and badly organized. Most HCV research 
activities have also been carried out by research centres 
of the Ministry of Health whereas less attention has been 
paid to socio-cultural and economic dimensions.
“Perhaps due to cultural problems associated with at-
titudes towards HCV in the Iranian society, schools, uni-
versities, and centres that do not have the task of inform-
ing about various health-related issues important for the 
community are less likely to inform about the disease”.
Most health services in Iran are based on a public sec-
tor model. PHC is completely free, and in addition to 
state-sponsored subsidies, health insurance also covers a 
portion of the health-care generated costs. Medical uni-
versities affiliated with the Ministry of Health and So-
cial welfare hospitals provide healthcare related to HCV 
patients. All PHC activities are provided in the public 
sector. Many of these hospitals have good laboratories 
to detect HCV. 
“Diagnostic capacities in Iran have grown dramatically 
in recent years, and therefore there is no problem in di-
agnosing HCV patients. On the one hand, the govern-
ment should have a lot of financial support for managing 
these patients. On the other hand, in my opinion, if all 
the costs of these patients would be free, patients would 
be more interested in the treatment and this could pre-
vent further outbreaks of the disease”.
Screening and active case finding play an important role 
in preventing the transmission of disease. The introduc-
tion of the family physician in some villages in Iran in 
1997, the community-based training, the referral of sus-
pect case, the early detection and treatment demonstrat-
ed to be effective strategies to prevent and control HCV. 
However, these strategies have not been implemented all 
over the country and therefore their advantages are not 
nationwide. 
“One of the benefits of a family doctor is the timely 
screening of people suspected of HCV. If the family doc-
tor in Iran was fully implemented, this could prevent and 
screen many illness cases in Iran”.
Diagnosis and treatment of HCV patients are important, 
especially if defined and provided through a multi-pro-
fessional evaluation. Hepatitis network  –  that includes 
gastroenterologists, specialists in infectious disease and 
general practitioners – implemented locally, in order to 
avoid patient transfer to the capital which implies pay-
ing for travel and accommodation, should be considered. 
Despite this, some service providers are not willing to 
cooperate in treating HCV patients for various reasons. 
“Unfortunately, some doctors in Iran do not believe that 
HCV patients can be treated and, therefore, are unwill-
ing to collaborate in providing services”.
Pharmaceutical companies have recently begun to pro-
duce HCV drugs and insurers have sponsored domes-
tic medications and put them on the list of medications 
they support. Of course, in some cases, people who tend 
to use foreign drugs should pay some of the cost of the 
treatment. The main concern is about people who do not 
have insurance coverage and must have out-of-pocket 
payments.
“In all countries, drug companies are providing medi-
cines and meeting with the needs of patients. In recent 
years, some companies have imported drugs due to lack 
of manufacturing technology. This has caused problems 
for patients, and insurers did not have the desire to sup-
port and cover for the cost of these drugs, but with the 
pursuit of authorities in Iran, some companies have 
begun to produce drugs locally, which significantly re-
duced costs”.
Neighbourhood with Pakistan or other countries with 
high HCV rates and Afghanistan as the largest drug pro-
ducer in the world have led to the highest transit of nar-
cotics from Iran. This has resulted into an increase in the 
number of injecting drug users in recent years. Cupping 
and tattooing are also rising as factors contributing to the 
spread of HCV infection.
“HCV disease, like many diseases, depends on several 
national and international variables. The prevalence of 
HCV in neighbouring countries is a dangerous alarm 
for the Iranian health sector. The high security level in 
Iran has caused many immigrants to decide to live in 
this country, and so we have to think in terms of various 
communicable diseases, including HCV, for properly 
screening them”.
One of the weaknesses in the health sector in Iran is the 
lack of a framework to prioritize the main problems in 
this area. It seems that if Iranian had a proper informa-
tion system, it could have a better prioritization of ill-
nesses and this would help administrators in planning. 
Local and regional data on HCV, especially in high-risk 
groups, are not available in many Iranian provinces. 
Hence, planning for these groups is difficult without 
proper evidence.
“Despite the many problems that HCV can have for any 
country, Iran has still major weaknesses in the informa-
tion gathering system for these patients. Researcher, in 
view of the role of information in planning for disease 
control, should conduct research in the general popula-
tion and at-risk groups in different provinces”.
Like many countries that have committed to the SDGs 
to eliminate HCV by 2030, health policy- and decision-
makers are aware both of the importance and of the 
problems that this disease can cause to Iran, and there-
fore they are trying to implement effective policies to 
achieve this international goal.
“Iran has been struggling to achieve international goals 
in recent years. In terms of the Millennium Development 
Goals (MDGs), Iran has been able to improve its health 
indicators and achieve its goals. So, policy- and deci-
sion-makers are trying to reach the goals of the SDGs, 
which makes it possible to eliminate HCV”.
There are limited financial resources in the health sec-
tor in all countries. In Iran, in recent years, there has 
been limited funding available for educational programs, 
activities and treatment for HCV patients, but, after the 
implementation of the Health Development Plan, funds 
were provided by the Ministry of Health. The plan made 
the processes associated with these patients more promi-
nent and the government paid a large part of the cost of 
treatment.
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“Many health ministry staff members say that for health-
related problems, more spending and new financial re-
sources are needed. In the last decades, health has been 
considered as a very important priority. We should take 
this opportunity and use the new financial resources for 
health challenges like HCV”.
The health sector, however, faces a shortage of human 
resources. There are shortages of nurses in many hos-
pitals. In some provinces there is a shortage of special-
ized physicians. Given the attitudes of some providers 
about infectious diseases and the hardships they should 
undergo during HCV treatment processes; they expect to 
receive better payments. Low salaries for nurses, failure 
to enforce tariffs for services for them, low tariffs for 
internal and external medical practitioners, delay in re-
imbursement by insurers are some of the problems that 
healthcare providers have to face.
“Iran’s health system faces a serious shortage of human 
resources concerning all professional groups (from gen-
eral practitioners to specialists and nurses and other al-
lied health workers). The high volume of work for many 
employees has made them tired. This shortage reduces 
the quality of services provided and is also a threat to 
HCV. If we pay more for HCV service providers, we can 
improve the quality of services to patients”.
The private sector has currently no role to play in the 
provision of healthcare to these patients, but in the fu-
ture it could participate together with the government in 
providing management and treatment options to HCV 
patients.
“To reduce the volume of work in the public sector, some 
services can be provided by the private sector. Of course, 
in order to reduce costs for patients, the government has 
a lot to do for HCV together with the private sector”.
Content
A national survey would be required to determine the 
current state of HCV in Iran at the country level. This 
type of study can be of great help to policy- and deci-
sion-makers.
“There is no information on HCV based on a large 
study. If we can do this with the help of researchers, we 
can have a better and more realistic plan”.
In many years, governments have mandated many or-
ganizations to work on prevention, diagnosis and treat-
ment for all people in the community, and they have ac-
cepted such responsibility.
“In recent years, health policy- and decision-makers 
have been working to make HCV a top priority. The ef-
forts that have been made to diagnose, treat and educate 
have somewhat contributed to counteract and mitigate 
the burden of disease. However, for instance, the higher 
risk of HCV in co-infected people, such as those with 
HIV, has not yet been mentioned directly in important 
national documents. Once explicitly mentioned, more 
funds may be available to control the spread of infec-
tions”.
“One of the strengths associated with HCV is the exist-
ence of national and international collaborations for 
Iran. There is a good relationship between Iranian and 
international researchers. Iranian physicians are well-
known for their studies on HCV”.
Studies show that the content of the laws and the plans 
developed by policy- and decision-makers in Iran in-
creases the access to healthcare for patients. HCV 
screening and treatment is also a favourite target of poli-
cy-makers. They are trying to approve upstream legisla-
tion to support these patients.
Documents and policies indicate that Iran’s health sec-
tor is seeking to fulfil its international obligations. In 
particular, Iran is trying to achieve the 2030 target. The 
Health Ministry has been working to achieve this goal, 
in accordance with the WHO framework, in its four ar-
eas.
The Iranian Blood Transfusion Organization has been 
asked to screen all donated blood for HCV. This has pro-
vided access to healthy blood products. 
Considering that the number of HCV patients in Iran is 
increasing, screening for at-risk groups should be con-
sidered as an optimal strategy, including for example, 
HCV test before imprisonment, but this has not been yet 
fully implemented.
“Many people need blood to continue living. It is very 
good that today there is no problem in getting healthy 
blood. It costs a lot, but people are no longer concerned”.
The health sector plans to reduce HCV-related deaths by 
65% and to curb new HCV cases by 90% by 2030.
“In the action plan, the main goal of the health sector in 
relation to HCV is to achieve the goals of the SDGs and, 
in accordance with the WHO guidelines, it aims to be 
consistent with global goals and targets”.
For a better treatment and management of HCV patients, 
the health department has provided physicians with ad-
vice on delivering optimal services and improving pa-
tient recovery, as well as with national and international 
guidelines. Of course, valid and up-to-date global refer-
ences can also be used.
Actors
The most important actor who has the greatest impact 
on HCV policies in Iran is the MoHME. The ministry 
carries out extensive activities to support policies aimed 
at controlling the disease, including planning, funding, 
medical, educational and screening activities.
Several organizations in Iran have the responsibility to 
focus on activities such as screening, providing social, 
cultural, and financial support for patients and people 
at risk. However, there seems to be a kind of lack of ef-
fective collaboration between them. Moreover, some 
organizations are responsible for social protection of ad-
dicts, but little is done for a variety of reasons, such as 
lack of financial resources. In the meantime, screening 
in prisons has still to be fully implemented.
“It is not good that the entire workload related to HCV 
is up to the Ministry of Health. If at least some funding 
was provided by a number of organizations, this would 
help the Ministry of Health focus on patient care. If the 
dialogue between the Ministry of Health and other or-
ganizations is combined with practical action, we could 
see more success in reaching the SDGs”. 
M. BEHZADIFAR ET AL.
E114
NGOs and media associations do not currently play a 
major role in raising awareness about HCV society 
whereas members of the religious section in Iran have 
a good place among people, but it seems that there is no 
good cooperation between policy- and decision-makers 
and religious people due to the negative attitudes towards 
HCV in society and the lack of proper use of emerging 
information and communication technologies (ICTs).
“Many people use the information services of NGOs in 
Iran. In addition, with the recent development of vir-
tual networks and ICTs, these important facilities and 
infrastructures seem to have an enormous potential for 
education, which is still underused. These groups and 
networks can be used to change the attitudes of people 
towards the disease”.
The role of international organizations in coping with fi-
nancial issues related to HCV in Iran is currently minor, 
even though this is changing in the last years. For in-
stance, the WHO has been able to influence health poli-
cies by providing its own reports on HCV. Accordingly, 
the Iranian Ministry of Health has developed its plans 
and programs for the disease control and management in 
accordance with the framework of the WHO and other 
relevant international organizations.
One of the important actors in blood screening and blood 
supply for those in need is the Iran Blood Transfusion 
Organization. After 76 years, the organization has been 
required to screen all donated blood. Therefore, Iran has 
currently no problem in providing healthy blood.
“Undoubtedly, the policy of healthy blood in Iran has 
been very successful. Thanks to the efforts of the blood 
transfusion organization, in addition to screening ser-
vices, provision of healthy blood for the needs of at-risk 
groups is very desirable. Perhaps the free provision of 
these services has led many people to use them with 
great satisfaction”.
Pharmaceutical companies have been able to play an im-
portant role in the treatment process and in reducing the 
costs by producing locally HCV drugs. This has resulted 
in a decrease in the economic-financial burden that the 
Ministry of Health had previously to cope with. The pri-
vate sector has currently little to do with investing in the 
drug sector and providing diagnostic services, even if in 
the future there is room for its engagement and involve-
ment.
Finally, the Iran’s Hepatitis Network has a huge impact 
on the implementation of the program as a government 
group (identifying, recording patients’ information, and 
treating them).
“The Iran’s Hepatitis Network has done a very good job 
in the process of controlling and managing HCV. If not, 
most of the patients would be unaware of their status. 
They do a lot of educational and therapeutic activities”.
Process 
A key step in the HCV policy-making process in Iran has 
been the formation of a national hepatitis committee, in 
which key people were researchers, health policy- and 
decision-makers. The main tasks of the committee are 
policy-making and planning, management, monitoring 
and evaluation, training and guidance of activities re-
lated to HCV control programs. The committee has been 
created by the Ministry of Health. At the same time, var-
ious meetings with other organizations related to HCV 
programs have taken place and almost good decisions 
have been made to counteract the spread of HCV. In 
order to attract the cooperation and participation of all 
ministries, organizations and stakeholders in maintain-
ing and promoting the health of Iranian communities, 
the Council has helped create more cohesive programs 
through the formation of networks and the presence of 
many important members actively involved and engaged 
in HCV programs.
“The Hepatitis Country Committee in Iran has played a 
very important role in controlling hepatitis. People who 
are present in this committee have a high, reputed scien-
tific and political status. The presence of these people is 
a great opportunity to implement large-scale programs 
to eliminate or at least control HCV”.
The most important source of funding for health sector 
programs in Iran is provided by the Parliament based on 
a proposal from the government. Like many countries, 
many lobbyists are trying to use funds in other sectors, 
but the most important point is that most members of 
Parliament (MPs) are paying particular, increasing at-
tention to health and related programs. The Ministry 
of Health is in charge of meeting with the needs of the 
health sector and interacts with the government and par-
liament.
“In recent years, the Ministry of Health has implemented 
several good plans and Iranian policy- and decision-
makers have opened new perspectives by providing 
better services and addressing community health prob-
lems. Effective conversations and interactions between 
the Ministry of Health and policy- and decision-makers 
have been conducted to get their comments and feed-
backs on how to effectively run the programs”.
Most HCV-related policies are top-down. There is a 
great deal of work and activities to carry out related 
to healthcare in the health sector, and as a result of the 
problems with the treatment of HCV patients, there are 
some processes that are prolonged. Some organizations 
do not fulfil their duties and all the expectations from the 
Ministry of Health are confronting this important chal-
lenge. All relevant stakeholders should be more actively 
engaged in HCV-related policies and plans. 
“One of the main challenges in Iran’s health system is 
its doctor-centeredness. Many physicians manage many 
departments. The treatment perspective is dominant. If 
some members of the staff who perform executive activi-
ties are used in the training, some policies and programs 
would be more realistic to run. Many services offered 
should be presented as long-term processes and objec-
tives”.
With the arrival of the President Rouhani, the estab-
lishment of his government and the launch of a broad 
health promotion plan, the availability of new financial 
resources, the need of controlling the increase in injecta-
ble drug users and the obligations of SDGs for Iran have 
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been considered as a good opportunity for HCV-related 
policies to be put into action and to be implemented.
“The Health Transformation Plan has many good 
strengths. With regard to new activities that can be used 
to provide services to marginalized settings and those 
who do not have a proper financial situation, prevention 
and control programs can be further implemented”.
The role of service providers in PHC and nurses in the 
provision of services should be given more attention.
Moreover, the lack of proper implementation of the re-
ferral system is one of the weaknesses of the health sec-
tor. Unfortunately, despite the role of PHC, patients are 
only aware of their illnesses in hospitals and do not use 
PHC services to monitor the treatment. If PHC collabo-
rated more extensively, it would be easier for patients to 
have more adequate time and space.
“The potential of the PHC network for HCV is not fully 
exploited. A large number of Iranian communities, es-
pecially those living in villages, would be interested in 
using these services. There must be a simple and up-to-
date program for them”.
Finally, there is no specific mechanism for evaluating 
HCV policies in the country. The evaluations are mostly 
individual, personal, cross-sectional rather than longitu-
dinal, limited, with short-term organizational goals, and 
there is no specific structure and system for it. The relat-
ed organizations have carried out independent monitor-
ing activities, which are largely interrupted, inadequate 
and non-conclusive.
“In recent years, evaluation has not been carried out on 
programs for the training, screening and treatment of 
HCV. The weaknesses and strengths of these programs 
are not clear. The Ministry of Health must have an ap-
propriate evaluation system in cooperation with other 
independent organizations”.
Discussion 
The present study comprehensively addressed HCV-
related policies and programs in Iran. The findings of 
this study emphasized the impact and complexity of 
various factors for policy making. Policy analysis has 
shown that for the development and implementation of a 
health program, some barriers that prevent it from being 
properly implemented should be identified and properly 
removed. Therefore, in order to investigate the health 
sector’s challenges, we must correctly identify the prob-
lems and consider the various options for solving them 
and consider the different issues at the implementation 
stage [31].
Using a policy model, this study examined the various 
dimensions of HCV in Iran. More in detail, in the con-
text of HCV, one of the major barriers that policy- and 
decision-makers in Iran have been unable to properly 
defeat is illness-related stigma. This has caused many 
people not to be educated enough concerning HCV and 
be afraid of individuals infected [32]. The lack of trust 
in information and the lack of mass media use has led 
to a lack of public awareness in Iran [33]. Policy- and 
decision-makers have had a lot of problems in raising 
social awareness of diseases such as HCV and HIV [34]. 
One of the major challenges associated with HCV con-
trol is the lack of awareness among the general popu-
lation and health workers. Supporting educational pro-
grams by government and relevant organizations is of 
paramount importance [35]. The Ministry of Health can 
exploit national TV to raise awareness about HCV. In 
recent years, people have become more aware of HIV 
through the use of television, radio, social media, and 
people who have a great impact on the general public’s 
perception of HIV (the so-called advocacy). Policy- and 
decision-makers can make use of the experience gained 
in this area to change people’s awareness and attitudes 
towards HCV in Iran.
HCV can have devastating effects on the economies of 
the countries, and therefore adequate funds for control-
ling this disease, in addition to those for preventing the 
transmission of the disease, would counteract the loss of 
funds imposed by the disease [36]. In recent years, fund-
ing for treating patients has been a major concern for the 
Ministry of Health, who has been working to provide 
good support for people who are not able to pay for the 
treatment.
Regarding the content of existing HCV-related policies 
in Iran, there is no specific reference to HCV in macro 
policies. There are many programs and activities in the 
form of guidelines issued by the Ministry of Health, al-
though organizations and health departments are not di-
rectly instructed. In this regard, the National Committee 
on Hepatitis in Iran has been working to guide physi-
cians, staff and other organizations. 
Considering that Afghanistan as the neighbouring coun-
try of Iran is the largest producer of narcotics and given 
the high volume of immigration, Afghanistan’s health 
policy- and decision-makers need to be involved in con-
trolling HCV refugees. Unfortunately, despite the fact 
that many people from Afghanistan migrate to Iran an-
nually, international organizations do not actually donate 
funds to Iran to improve their health [37]. Therefore, the 
Ministry of Health needs international financial resourc-
es for the screening and treatment of Afghan refugee pa-
tients [38]. 
The findings of this study showed that the major prob-
lems with the HCV programs is how policies have been 
designed (most of them are top-down) and the lack of 
use of comments and feedbacks from relevant stakehold-
ers. When decision- and policy-makers do not use the 
views of individuals who run the executive process of 
a policy, it seems to be difficult to achieve the desired 
goals [39]. Furthermore, existing evidence suggests that 
physicians and other relevant stakeholders should be in-
volved in the HCV policy-making processes. 
In addition to specialized hospitals and clinics, the PHC 
health services network plays an important role in pro-
viding educational, health and therapeutic services. The 
potential of this network has not been fully exploited for 
the purpose of patients, so doctors working in this net-
work have still much to offer to patients with HCV [40].
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Other points to be noted are that the policies that have 
been taken to control HCV are at a national level and 
have not or little responded to local priorities, especial-
ly in areas with high-risk factors for transmitting and 
spreading the disease [41].
Because of the high level of healthcare bureaucracy, 
policies aimed at controlling HCV should be quickly 
implemented. In some cases, such as insurance services 
and subsidies for patients, the government must notify 
the organizations to enforce them, but, in other cases, it 
seems that the length of approval and implementation is 
too long, and hence the effectiveness of these policies is 
less than that expected [42]. 
Despite the existence of national data on vulnerable 
groups, there are still not many local data. In addition, 
many policies that are introduced on the basis of these 
data encounter many problems and issues during the 
implementation phase. In order to properly implement 
policies, they should be presented clearly and without 
any ambiguity. One of the important reasons for this 
lack of proper implementation is the weakness during 
the step of knowledge translation and the lack of effec-
tive communication between policy-, decision-makers 
and researchers [43]. 
Many stakeholders are involved in the process of control-
ling HCV in Iran. One of the challenges is the lack of ap-
propriate interactions between the actors and the various 
organizations. Due to the fact that the national documents 
do not refer directly to HCV, the tasks of the organizations 
are not exactly defined. Of course, there are activities for 
each of them, but many organizations consider the Min-
istry of Health as the main actor and responsible for the 
plans; practically, activities that are relevant to the cultur-
al, social and economic structures of society and patients 
are not properly implemented. For example, many inject-
ing drug users are faced with plenty of economic prob-
lems that should be addressed. On the other hand, many 
stakeholders only consider the treatment of patients and 
have forgotten other issues such as education, culture, and 
protection of high-risk groups. 
There is no doubt that the most important and power-
ful actor in charge of the HCV control program in Iran 
is the Ministry of Health, but the Ministry alone cannot 
do all the activities. Other organizations must fulfil their 
obligations. This commitment is in the fields of educa-
tion, screening and treatment  [44]. Health policy- and 
decision-makers need broad support to implement their 
HCV control policies [45]. 
As in many countries in the world, people using inject-
ing drugs are the most important sources of HCV trans-
mission in Iran [46], as well as prisoners [19]. Evidence 
suggests that screening and treatment activities among 
these people should be seriously addressed by policy- 
and decision-makers to prevent HCV [47], implement-
ing strategies such as needle and syringe programs 
(NSPs) and opioid substitution therapy (OST) [48, 49]. 
In recent years, the Ministry of Health has set up cen-
tres to provide services to reduce harm and prevent the 
transmission of communicable diseases such as HIV and 
HCV [50].
These policies can be effective in reducing HCV trans-
mission in Iran, but despite the positive attitude of prison 
staff towards implementing these policies, some offi-
cials and managers have little commitment and motiva-
tion [51] and many people who inject drugs (PWID) do 
not use the services of the centres.
Moreover, the evaluation of services provided in the 
HCV program has not yet been taken seriously by pol-
icy- and decision-makers  [52]. The Ministry of Health 
and other organizations should implement the evaluation 
of HCV-related programs. 
Our study has some strengths: it is one of the first studies, 
if not the first, focusing on HCV-related policies in the 
WHO Eastern Mediterranean Regional Office (EMRO) 
region, which is a geographical area with a high HCV 
incidence. Regarding the triangle policy framework, 
various aspects of HCV were studied. To increase the 
credibility and reliability of the data, after evaluating the 
results, a group of experts was involved and consulted in 
the various steps of the research. 
On the other hand, our study has some limitations. Some 
people were not willing to be interviewed. As such, the 
sample recruited may be not representative of all the 
stakeholders involved in HCV-related policies. 
Conclusions 
The findings of this study, based on the policy triangle 
framework as a model of policy analysis, showed that 
various factors can affect HCV policy in Iran. Certain 
cultural problems caused by stigma can impact on aware-
ness-raising processes. It is also necessary to consider 
HCV directly in the context of governmental policies. All 
relevant stakeholders, including the private sector, should 
be involved. The findings of this study can provide good 
information for improving, supporting and developing 
policy processes in Iran. Evidence-based planning, epide-
miological surveys conducted in Iranian provinces char-
acterized by HCV prevalence rates, support for up-to-date 
policies and resource mobilization are needed to achieve 
the ambitious goal of HCV elimination by 2030.
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